The antibodies against coronavirus SARS-CoV-2 can last up to 12 months in more than 70% of the patients who have passed the covid, according to a study published by chinese researchers collected by the official media of the Asian country on Friday, July 8, 2021-
The research also concludes that the vaccination it can “effectively restrict the spread” of the coronavirus by promoting an immune response similar to the way human bodies generate human antibodies against live viruses.
The study was carried out by a subsidiary of the state pharmaceutical Sinopharm -which produces two of the vaccines approved by the Chinese government- and the National Research Center for Translational Medicine at Jiaotong University in Shanghai.
For your elaboration, some 1,800 convalescent plasma samples were collected from 869 people who overcame COVID in the previous 12 months in Wuhan, the central Chinese city where the first global outbreak of the coronavirus was recorded in December 2019.
The researchers checked the presence and amount in these samples of the RBDIgG, a kind of antibody indicating the strength of immunity against virus, explains the official newspaper China Daily.
According to the results, in nine months the levels of antibodies fell to 64.3% from the level when patients contracted the virus, and since then they stabilized until the twelfth month.
The immune response was stronger in men than in women during the early stages of infection, but the difference was diluted with time until almost disappearing after twelve months.
Also, people in the 18 to 55 age group developed higher levels of antibodies.
According to him China National Biotechnology Group -the subsidiary of Sinopharm that elaborated it-, this study is the most extensive of those that have verified the continuity of the immune response in patients recovered from covid.
–
